Innovent Biologics's total assets for Q2 2024 were ¥20.30B, a decrease of -1.61% from the previous quarter. HK:1801 total liabilities were ¥7.87B for the fiscal quarter, a -2.85% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.